Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1148/radiol.2483071407
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cui, Y.
Right arrow Articles by Shen, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Cui, Y.
Right arrow Articles by Shen, L.
(Radiology 2008;248:894-900.)
© RSNA, 2008

Gastrointestinal Imaging

Apparent Diffusion Coefficient: Potential Imaging Biomarker for Prediction and Early Detection of Response to Chemotherapy in Hepatic Metastases1

Yong Cui, PhD, Xiao-Peng Zhang, MD, Ying-Shi Sun, MD, Lei Tang, MD, and Lin Shen, MD

1 From the Departments of Radiology (Y.C., X.P.Z., Y.S.S., L.T.) and Digestive Diseases (L.S.), Peking University School of Oncology, Beijing Cancer Hospital and Institute, 52 Fu Cheng Road, Hai Dian District, Beijing 100036, People's Republic of China. Received August 7, 2007; revision requested October 12; revision received December 21; accepted February 19, 2008; final version accepted March 19. Supported by the National Basic Research Program of China (973 Program) (No. 2006CB705706). Address correspondence to X.P.Z. (e-mail: zxp{at}bjcancer.org).

Purpose: To evaluate the ability of the apparent diffusion coefficient (ADC) to help predict response to chemotherapy in patients with colorectal and gastric hepatic metastases.

Materials and Methods: Institutional review board approval was obtained; all patients provided informed consent. Standard magnetic resonance (MR) imaging and diffusion-weighted (DW) MR imaging were performed before and 3, 7, and 42 days after initiating chemotherapy for 87 hepatic metastases in 23 colorectal and gastric cancer patients (16 men, seven women; mean age, 55.7 years; range, 33–71 years). Lesions were classified as either responding or nonresponding, according to changes in size at the end of therapy. Linear mixed-effects modeling was applied to analyze change in ADCs and size following treatment. The Pearson correlation test was calculated between those ADC parameters and tumor response.

Results: Thirty-eight responding and 49 nonresponding metastatic lesions were evaluated. Pretherapy mean ADCs in responding lesions were significantly lower than those of nonresponding lesions (P = .003). An early increase in ADCs (on day 3 or 7) was observed in responding lesions but not in nonresponding lesions (P = .002). Weak but significant correlations were found between final tumor size reduction and both pretreatment ADCs (P = .006) and early ADC changes (day 3, P = .004; day 7, P < .001).

Conclusion: ADC seems to be a promising tool for helping predict and monitor the early response to chemotherapy of hepatic metastases from colorectal and gastric carcinomas.

© RSNA, 2008




This article has been cited by other articles:


Home page
 RadioGraphicsHome page
R. C. Jha, C. S. Whittaker, A. Coady, L. Culver, G. Rustin, M. Padwick, and A. R. Padhani
Invited Commentary * Authors' Response
RadioGraphics, May 1, 2009; 29(3): 774 - 778.
[Full Text] [PDF]